Trial Profile

HEALEY ALS Platform Trial - Regimen I NUZ-001

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Feb 2026 Status changed from not yet recruiting to recruiting.
06 Oct 2025 According to the Neurizon Therapeutics Media Release, with IND now active, company anticipates Mass General Hospital (MGH) filing a protocol amendment to their IND for the HEALEY ALS Platform Trial to incorporate our specific protocol regimen early in the coming weeks. Company expects to initiate patient enrollment in the HEALEY ALS Platform Trial in Q4 CY2025.
06 Oct 2025 According to the Neurizon Therapeutics Media Release, company announced U.S. Food and Drug Administration (FDA) has lifted the clinical hold on NUZ-001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS Platform Trial, expected to commence Q4 CY2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com